(b)
| Reference | [4] | [5] | [6] | [7] | [8] (TIW) | [8] (QD) | [9] | [10] | [11] | [12] | Total number (P/p) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total number of patients (P/p) | 55 (28/27) |
24 (16/8) |
118 (57/61) |
78 (40/38) |
145 (72/73) |
75 (35/40) |
220 (107/113) |
29 (15/14) |
88 (61/27) |
281 (186/95) |
1113 (617/496) |
| 30% decrease in iPTH levels for two consecutive measures (P/p) | — | — | 113 (54/59) |
78 (40/38) |
138 (68/70) |
71 (33/38) |
209 (101/108) |
29 (15/14) |
82 (58/24) |
— | 720 (369/351) |
| Mean eGFR change from baseline to the final visit (P/p) | — | — | 118 (57/61) |
— | 117 (57/60) |
58 (25/33) |
175 (82/93) |
— | — | — | 468 (221/247) |
| Incidence of hypercalcemia (P/p) | 55 (28/27) |
— | — | — | 140 (69/71) |
74 (35/39) |
209 (101/108) |
29 (15/14) |
87 (61/26) |
281 (186/95) |
875 (495/380) |
| Incidence of hyperphosphatemia (P/p) | 55 (28/27) |
— | — | — | 140 (69/71) |
74 (35/39) |
209 (101/108) |
— | — | — | 478 (233/245) |
| Elevation in Ca × P product levels (P/p) | — | — | — | — | 140 (69/71) |
74 (35/39) |
209 (101/108) |
— | — | — | 423 (205/218) |
| Reduction in proteinuria | 55 (28/27) |
22 (15/7) |
— | — | — | — | — | — | — | 272 (184/88) |
349 (227/122) |
P: Paricalcitol group; p: placebo group.